My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.00 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Why BioMarin Shares Are Plunging Today? ↗

March 06, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating ↗

March 03, 2023

On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.

Via Investor's Business Daily

uniQure Stock Trying To Close In On Key Technical Measure ↗

February 28, 2023

uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.

Via Investor's Business Daily

BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023 ↗

February 28, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023 ↗

February 22, 2023

Via Benzinga

BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst ↗

January 30, 2023

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Preview: Biomarin Pharmaceutical's Earnings ↗

February 24, 2023

Via Benzinga

Analyst Ratings for Biomarin Pharmaceutical ↗

February 22, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

3 Prime Healthcare Takeover Targets ↗

February 14, 2023

These three companies are attractive targets for their potential.

Via The Motley Fool

Moderna Stock Getting Closer To Key Technical Benchmark ↗

February 10, 2023

On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.

Via Investor's Business Daily

What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

January 30, 2023

Via Benzinga

6 Analysts Have This to Say About Biomarin Pharmaceutical ↗

January 11, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

January 10, 2023

Some stocks are hitting new highs.

Via The Motley Fool

Expert Ratings for Biomarin Pharmaceutical ↗

November 29, 2022

Via Benzinga

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

3 Drug Stocks With Promising Pipelines for 2023 ↗

January 23, 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Via InvestorPlace

Cramer Is Holding This Biotech Stock ↗

January 12, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).

Via Benzinga

Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗

January 11, 2023

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target ↗

January 11, 2023

Via Benzinga

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 01, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 01, 2022

Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate ↗

November 23, 2022

Via Benzinga

The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath ↗

November 23, 2022

And shares of its developer are on a warpath this week.

Via Investor's Business Daily

Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today ↗

November 23, 2022

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.